On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of Long kanker conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes tumor cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of melanoom (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
Squibb het bekend gemaak dat die maatskappy Opdivo se aansoek vir die behandeling van longkanker-indikasies by die FDA en die farmaseutiese administrasie van die EU ingedien het. Natuurlik sal die ambisieuse Squibb Company natuurlik nie net met longkanker en melanoom tevrede wees nie. Trouens, Squibb doen tans meer as 35 studies van Opdivo alleen of in kombinasie met ander middels om verskillende gewastipes te behandel. Volgens ontleders sal Opdivo se toekomstige verkope so hoog as 5 miljard Amerikaanse dollar bereik.
The cancer immunotherapie research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
Gedetailleerde Engelse verslag:
Bristol-Myers Squibb ($ BMY) se uitstaande immuno-o nkologie-middel nivolumab, wat verlede maand as Opdivo goedgekeur is, het 'n dawerende sukses behaal in 'n laat-stadium longkankerproef, wat verkoopsverwagtinge vir die baanbrekersbehandeling versterk het.
In 'n studie van 272 pasiënte wat Opdivo teen die standaard kankerdoder docetaxel stel, het Bristol-Myers-medisyne so 'n uitstekende algehele oorlewing in vergelyking met die beheerarm gedemonstreer dat dit sy primêre eindpunt voor skedule bereik het, wat gelei het tot die aanbeveling van die verhoor se datamoniteringskomitee. die studie vroeg gestaak word. Bristol-Myers nooi nou die pasiënte in die docetaxel-groep uit om in te teken op Opdivo deur middel van 'n oop-etiket uitbreidingstudie.
Bristol-Myers se behandeling is ontwerp om 'n immuunstelselaanval op gewasse te bewerkstellig deur 'n pad genaamd PD-1 te blokkeer, wat, ongekontroleerd, kankerselle toelaat om onopgemerk deur die liggaam se natuurlike verdediging te slaag. Soos Merck ($ MRK) se soortgelyke Keytruda, het Opdivo verlede jaar FDA-goedkeuring gekry as 'n behandeling vir melanoom, maar Bristol-Myers se medisyne staan alleen in longkanker, aangesien sy jongste kliniese sukses die eerste keer is dat 'n PD-1-remmer 'n oorlewingsvoordeel teen die siekte, het die maatskappy gesê.
Opdivo’s particular promise in longkanker wat nie klein is nie has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
Bristol-Myers het longkanker-aansoeke in die VSA en Europa ingedien vir Opdivo in longkanker, met die verwagting om die gebruik van die middel later vanjaar uit te brei.
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, kop en nek kanker, glioblastoma, Non-Hodgkin lymphoma and other cancers.
